Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
McKinsey
Colorcon
Dow
Chinese Patent Office
Accenture
Baxter
Daiichi Sankyo

Generated: November 13, 2018

DrugPatentWatch Database Preview

Latanoprost - Generic Drug Details

« Back to Dashboard

What are the generic sources for latanoprost and what is the scope of latanoprost patent protection?

Latanoprost is the generic ingredient in four branded drugs marketed by Sun Pharma Global, Akorn, Amring Pharms, Apotex Inc, Bausch And Lomb, Dr Reddys Labs Ltd, Fdc Ltd, Mylan, Sandoz Inc, and Pharmacia And Upjohn, and is included in eleven NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are twenty drug master file entries for latanoprost. Fifteen suppliers are listed for this compound. There is one tentative approval for this compound.

Pharmacology for latanoprost
Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog
Synonyms for latanoprost
(15R)-Latanoprost
(1R,2R,3R,5S,3''R)-7-[3,5-Dihydroxy-2-(3-hydroxy-5-phenyl-pentyl)-cyclopentyl]-hept-5-enoic acid isopropyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptanoic acid 1-methylethyl ester
(5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic Acid 1-Methylethyl Ester
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoic acid propan-2-yl ester
(Z)-isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
130209-82-4
155551-81-8
209L824
33537-EP2295409A1
33537-EP2311820A1
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester
5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1-alpha(Z),2-beta(R*),3-alpha,5-alpha))-
6Z5B6HVF6O
A806039
AB00640005-04
AB00640005-06
AB2000019
ABP001061
AC1NSK8Q
AKOS024458331
Ambap130209-82-4
AR-202
AT-3016
BDBM50240648
C26H40O5
Catioprost
CCG-100946
CHEBI:6384
CHEMBL1051
CPD000466354
CS-2758
D00356
D0C6NM
DB00654
DTXSID1041057
GAAP Ofteno
GGXICVAJURFBLW-CEYXHVGTSA-N
GTPL1961
HMS2051H11
HMS2089J17
HY-B0577
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
Isopropyl 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
Isopropyl-(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate
J-005764
Jsp001835
L-PPDS
L0262
L1167_SIGMA
latanoprost (isopropyl ester)
Latanoprost (JAN/USAN/INN)
Latanoprost [USAN:INN:BAN]
latanoprost free acid
Latanoprost, (+/-)-
Latanoprost, >=98% (HPLC), oil
Latanoprost, United States Pharmacopeia (USP) Reference Standard
latanoprostum
MFCD00216074
MLS000759468
MLS001424106
MolPort-003-942-862
NC00196
NCGC00246969-01
Nova-21027
PhXA 41
PHXA-41
PhXA34 [as 15(R,S)-isomer]
PhXA41
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-bis(oxidanyl)-2-[(3R)-3-oxidanyl-5-phenyl-pentyl]cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
s4709
SAM001246671
SC-18987
SCHEMBL24698
SMR000466354
ST24047444
T-2345
TL8000716
Tris(2,4-dimethylphenyl)phosphine-5,5',5""""-trisulfonic acid trisodium salt
UNII-6Z5B6HVF6O
UNII-8S5FB3XXG8 component GGXICVAJURFBLW-CEYXHVGTSA-N
XA 41
XA-41
XA41
Xalatan
Xalatan (TN)
ZINC12468792
Tentative approvals for LATANOPROST
Applicant Application No. Strength Dosage Form
➤ Try a Free Trial➤ Try a Free Trial0.005%SOLUTION; OPHTHALMIC

US Patents and Regulatory Information for latanoprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 AT RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sandoz Inc LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 091449-001 Mar 22, 2011 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan LATANOPROST latanoprost SOLUTION/DROPS;OPHTHALMIC 201786-001 Mar 22, 2011 AT RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sun Pharma Global XELPROS latanoprost EMULSION;OPHTHALMIC 206185-001 Sep 12, 2018 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for latanoprost

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn XALATAN latanoprost SOLUTION/DROPS;OPHTHALMIC 020597-001 Jun 5, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for latanoprost

Country Document Number Estimated Expiration
Ukraine 100393 ➤ Try a Free Trial
European Patent Office 2197449 ➤ Try a Free Trial
Ecuador SP10010167 ➤ Try a Free Trial
Eurasian Patent Organization 201070483 ➤ Try a Free Trial
Australia 2008344909 ➤ Try a Free Trial
South Korea 20100087107 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for latanoprost

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB97/014 United Kingdom ➤ Try a Free Trial PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
C0111 Belgium ➤ Try a Free Trial PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071
90031-1 Sweden ➤ Try a Free Trial PRODUCT NAME: LATANOPROST
C0128 France ➤ Try a Free Trial PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
/1997 Austria ➤ Try a Free Trial PRODUCT NAME: LATANOPROST UND SEINE THERAPEUTISCH AKTIVEN UND PHYSIOLOGISCH ANNEHMBAREN DERIVATE; NAT. REGISTRATION NO/DATE: 1-22019 19970627; FIRST REGISTRATION: SE 12716 19960718
70039 Netherlands ➤ Try a Free Trial PRODUCT NAME: [1R-[1 ALPHA (Z),2 BETA(R*),3 ALPHA,5ALPHA]]-7-[3,5-DIHYDROXY-2-(3-HYDROXY-5- FENYLPENTYL)CYCLOPENTYL]-5-HEPTEENZUUR, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN ESTER, IN HET BIJZONDER LATANOPROSTUM; NAT. REGISTRATION NO/DATE: RVG 21304 19970610; FIRST REGISTRATION: SE 12716 19960718
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Cantor Fitzgerald
McKinsey
Colorcon
Dow
Chinese Patent Office
Accenture
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.